Logo image of HQL

ABRDN LIFE SCIENCES INVESTOR (HQL) Stock Price, Quote, News and Overview

NYSE:HQL - New York Stock Exchange, Inc. - US87911K1007 - Currency: USD

13.08  -0.32 (-2.39%)

After market: 12.83 -0.25 (-1.91%)

Fundamental Rating

2

Taking everything into account, HQL scores 2 out of 10 in our fundamental rating. HQL was compared to 0 industry peers in the Unkown industry. While HQL seems to be doing ok healthwise, there are quite some concerns on its profitability. HQL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HQL has reported negative net income.
Of the past 5 years HQL 4 years were profitable.
In the past 5 years HQL always reported negative operating cash flow.
HQL Yearly Net Income VS EBIT VS OCF VS FCFHQL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

Industry RankSector Rank
ROA -2.92%
ROE -3.03%
ROIC N/A
ROA(3y)-0.41%
ROA(5y)7.25%
ROE(3y)-0.75%
ROE(5y)7.11%
ROIC(3y)N/A
ROIC(5y)N/A
HQL Yearly ROA, ROE, ROICHQL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

1.3 Margins

In the last couple of years the Profit Margin of HQL has declined.
The Profit Margin and Operating Margin and Gross Margin are not available for HQL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-8.83%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HQL Yearly Profit, Operating, Gross MarginsHQL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K 4K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, HQL has more shares outstanding
Compared to 5 years ago, HQL has more shares outstanding
HQL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HQL Yearly Shares OutstandingHQL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
HQL Yearly Total Debt VS Total AssetsHQL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 14.96 indicates that HQL is not in any danger for bankruptcy at the moment.
HQL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.96
ROIC/WACCN/A
WACCN/A
HQL Yearly LT Debt VS Equity VS FCFHQL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 0.42 indicates that HQL may have some problems paying its short term obligations.
HQL has a Quick Ratio of 0.42. This is a bad value and indicates that HQL is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.42
Quick Ratio 0.42
HQL Yearly Current Assets VS Current LiabilitesHQL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for HQL have decreased strongly by -129.58% in the last year.
HQL shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.08% yearly.
The Revenue for HQL has decreased by -10.15% in the past year. This is quite bad
The Revenue has been growing by 10.28% on average over the past years. This is quite good.
EPS 1Y (TTM)-129.58%
EPS 3Y5.08%
EPS 5YN/A
EPS Q2Q%-189.13%
Revenue 1Y (TTM)-10.15%
Revenue growth 3Y20.23%
Revenue growth 5Y10.28%
Sales Q2Q%-34.3%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HQL Yearly Revenue VS EstimatesHQL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

HQL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HQL Price Earnings VS Forward Price EarningsHQL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HQL Per share dataHQL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 14.45%, HQL is a good candidate for dividend investing.
HQL's Dividend Yield is rather good when compared to the S&P500 average which is at 2.35.
Industry RankSector Rank
Dividend Yield 14.45%

5.2 History

HQL has been paying a dividend for at least 10 years, so it has a reliable track record.
HQL has decreased its dividend recently.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
HQL Yearly Dividends per shareHQL Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2

5.3 Sustainability

DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
HQL Yearly Income VS Free CF VS DividendHQL Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

More info and screens

ABRDN LIFE SCIENCES INVESTOR

NYSE:HQL (7/11/2025, 8:21:04 PM)

After market: 12.83 -0.25 (-1.91%)

13.08

-0.32 (-2.39%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)06-09 2025-06-09
Earnings (Next)12-22 2025-12-22
Inst Owners30.71%
Inst Owner Change0%
Ins Owners0.01%
Ins Owner Change0%
Market Cap377.62M
Analysts0
Price TargetN/A
Short Float %0.16%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield 14.45%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years1
Div Non Decr Years1
Ex-Date05-22 2025-05-22 (0.43)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 115.48
P/FCF N/A
P/OCF N/A
P/B 0.95
P/tB 0.95
EV/EBITDA N/A
EPS(TTM)-0.42
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.11
BVpS13.72
TBVpS13.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.92%
ROE -3.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-0.41%
ROA(5y)7.25%
ROE(3y)-0.75%
ROE(5y)7.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-8.83%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.42
Quick Ratio 0.42
Altman-Z 14.96
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-129.58%
EPS 3Y5.08%
EPS 5YN/A
EPS Q2Q%-189.13%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-10.15%
Revenue growth 3Y20.23%
Revenue growth 5Y10.28%
Sales Q2Q%-34.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A